Daiwa Securities Group Inc. Purchases 21,854 Shares of Bristol Myers Squibb Company $BMY

Daiwa Securities Group Inc. boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 545,396 shares of the biopharmaceutical company’s stock after acquiring an additional 21,854 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Bristol Myers Squibb were worth $29,419,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Physician Wealth Advisors Inc. increased its position in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares in the last quarter. EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb in the 4th quarter valued at about $32,000. KERR FINANCIAL PLANNING Corp bought a new stake in Bristol Myers Squibb in the 3rd quarter valued at about $35,000. Finally, Garner Asset Management Corp bought a new stake in Bristol Myers Squibb in the 4th quarter valued at about $35,000. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $57.24 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The stock’s 50 day moving average price is $58.10 and its 200-day moving average price is $56.52. The company has a market capitalization of $116.88 billion, a PE ratio of 16.08, a PEG ratio of 0.16 and a beta of 0.24. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the prior year, the business earned $1.80 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for previously untreated stage III or IV classical Hodgkin lymphoma in the EU, which could expand Bristol Myers Squibb’s reach in a key oncology market. How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
• Positive Sentiment: At ASCO 2026, Bristol Myers Squibb highlighted promising late-stage cancer data, including Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and survival data for izalontamab brengitecan, reinforcing the company’s pipeline momentum. Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
• Positive Sentiment: Arcus Biosciences and Bristol Myers Squibb expanded their kidney cancer collaboration to advance casdatifan combinations in ccRCC, giving BMY another clinical-development opportunity in oncology. Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
• Neutral Sentiment: Several articles noted that Bristol Myers Squibb remains attractive to value and dividend-focused investors, with commentary pointing to its yield and dividend durability rather than a major near-term catalyst. Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
• Neutral Sentiment: Bristol Myers Squibb also drew attention from an options-volume report, suggesting heightened trading interest, though the item did not point to a specific fundamental driver. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)

Analyst Ratings Changes

A number of brokerages have commented on BMY. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Barclays began coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective for the company. HSBC boosted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Finally, Cantor Fitzgerald boosted their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.